Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges-Reference-Cited by-同舟云学术

Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges

Published:2021-09-11 Issue:10 Volume:20 Page:1291-1309
ISSN:1476-0584
Container-title:Expert Review of Vaccines
language:en
Short-container-title:Expert Review of Vaccines

Author:

Horn Emily K¹^ORCID,Wasserman Matt D¹^ORCID,Hall-Murray Cassandra²^ORCID,Sings Heather L²,Chapman Ruth³,Farkouh Raymond A¹

Affiliation:

1. Health Economics and Outcomes Research, Pfizer Inc, New York, NY, USA

2. Vaccines Medical Development and Scientific and Clinical Affairs Pfizer, Inc, Collegeville, PA, USA

3. Evidera Market Access Ltd, The Ark, London, UK

Funder

Pfizer Inc

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,Molecular Medicine,Immunology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14760584.2021.1971521

Reference84 articles.

1. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines

2. World Health Organization. Pneumococcal conjugate vaccines in infants and children under 5 years of age: WHO position paper – february 2019. [Internet]. Weekly Epidemiological Record. 2019. Available from: http://www.who.int/immu-%0Ahttps://www.who.int/immunization/policy/position_papers/who_pp_pcv_2019_summary.pdf?ua=1.

3. Which individuals are at increased risk of pneumococcal disease and why? Impact of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive pneumococcal disease: Table 1

4. World Health Organization (WHO). Estimated Hib and pneumococcal deaths for children under 5 years of age, 2000 [Internet]. 2014 [cited 2021 Jan 29]; Available from: https://www.who.int/immunization/monitoring_surveillance/burden/estimates/Pneumo_hib_2000/en/.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pneumococcal Vaccine Breakthrough and Failure in Infants and Children: A Narrative Review;Vaccines;2023-11-24

2. Vaccinating Welders against Pneumococcus: Evidence from a Systematic Review and Meta-Analysis;Vaccines;2023-09-15

3. Cost-effectiveness analysis of PCV20 to prevent pneumococcal disease in the Canadian pediatric population;Human Vaccines & Immunotherapeutics;2023-08

4. Estimating the Cost-Effectiveness of Switching to Higher-Valency Pediatric Pneumococcal Conjugate Vaccines in the United Kingdom;Vaccines;2023-06-28

5. Pneumococcal Vaccination in Children: A Systematic Review and Meta-Analysis of Cost-Effectiveness Studies;Value in Health;2023-04